Investors don’t buy hype. They buy data, direction, and durability. That’s exactly what you need when evaluating Tempus AI stock.
This guide breaks down everything that matters — the business model, stock price performance, financials, valuation, risks, and long-term forecast. No fluff. No vague claims. Just clear analysis written in plain English.
If you’re wondering whether Tempus AI stock (TEM) deserves a spot in your portfolio, keep reading.
Tempus AI at a Glance
Company: Tempus AI
Ticker: TEM
Exchange: NASDAQ
Sector: AI Healthcare / Precision Medicine
Founded: 2015
Headquarters: Chicago, Illinois
Tempus AI operates at the intersection of artificial intelligence, genomics, and clinical diagnostics. The company builds a massive data platform that helps doctors personalize treatment decisions. It also partners with pharmaceutical firms that need structured clinical data for drug development.
In simple terms, Tempus collects clinical data, structures it using AI, and monetizes it through diagnostics and data services.
That’s powerful.
However, power alone doesn’t guarantee shareholder returns. You need revenue growth, margin expansion, and capital discipline. Let’s dig deeper.
What Tempus AI Actually Does
You can’t evaluate Tempus stock without understanding how it makes money.
Tempus AI combines:
- Clinical diagnostics (genomic testing)
- AI-powered data analytics
- Real-world evidence platforms
- Pharmaceutical partnerships
Business Model Breakdown
Tempus generates revenue through two primary engines:
Diagnostics Segment
- Genomic sequencing for oncology patients
- Molecular profiling
- Personalized cancer treatment insights
Data & Services Segment
- Clinical data licensing
- AI-driven insights for pharmaceutical companies
- Research collaborations
Think of it like this:
The diagnostics side feeds the data machine.
The data machine powers high-margin AI insights.
That flywheel matters. Data compounds over time. More data improves AI. Better AI attracts more partners.
Tempus AI IPO and Public Listing Details
Tempus AI went public in 2024 on NASDAQ under the ticker TEM.
Here’s what matters to investors:
| Metric | IPO | Recent Trading Range |
|---|---|---|
| IPO Price | ~$37 per share | Volatile since listing |
| Exchange | NASDAQ | NASDAQ |
| Ticker | TEM | TEM |
| Shares Outstanding | Public float post-IPO | Updated quarterly |
The IPO valued Tempus in the multi-billion-dollar range. However, post-IPO volatility has been elevated.
Why?
- AI sector enthusiasm
- Healthcare reimbursement uncertainty
- Investor scrutiny on profitability
- Macro rate environment
Young public companies often swing hard in their first year. That doesn’t mean failure. It means price discovery.
Tempus AI Stock Price Today (TEM)
When evaluating Tempus AI stock price today, investors focus on:
- Market cap
- 52-week high and low
- Average daily trading volume
- Volatility
- Institutional ownership
Key Market Metrics Snapshot
| Metric | Approximate Range |
|---|---|
| Market Cap | Multi-billion valuation |
| 52-Week High | Post-IPO high |
| 52-Week Low | Volatility-driven pullback |
| Avg Volume | Strong liquidity |
| Beta | Above market average |
High beta means higher swings. This isn’t a slow dividend stock. It’s a growth play.
Tempus AI Financial Performance
Numbers tell the truth. Let’s examine them carefully.
Revenue Growth
Tempus has demonstrated strong top-line growth in recent years.
| Year | Revenue (Approx) | YoY Growth |
|---|---|---|
| 2022 | ~$321M | — |
| 2023 | ~$531M | ~65% |
| 2024 | Continued growth trend | Expanding |
That growth rate puts Tempus among faster-growing AI healthcare stocks.
However, revenue alone isn’t enough.
Profitability
Tempus has historically operated at a net loss. That’s common for data-heavy growth companies.
Key financial considerations:
- High R&D investment
- Infrastructure buildout costs
- Data acquisition expense
- Sales expansion
Margins in diagnostics tend to be lower. Data services typically carry higher margins. Investors watch for margin mix improvement.
Cash Position and Burn Rate
Cash determines survival.
Growth companies must balance:
- Expansion
- Research
- Operating losses
- Capital raises
Investors should monitor:
- Cash and equivalents
- Quarterly burn
- Debt obligations
- Dilution risk
If revenue growth accelerates while burn slows, that’s bullish.
Tempus AI Fundamentals and Valuation
Valuation often drives short-term stock moves.
Common Valuation Metrics
| Metric | Why It Matters |
|---|---|
| Price-to-Sales (P/S) | Useful for unprofitable growth stocks |
| Enterprise Value | Includes debt |
| Gross Margin | Signals scalability |
| Revenue Growth | Core driver |
AI healthcare stocks typically trade at premium multiples due to:
- Large addressable markets
- AI narrative
- Data defensibility
The real question is whether Tempus can justify its valuation through sustained growth.
Competitive Landscape: AI Healthcare Stocks
Tempus operates in a competitive arena.
Key competitors include:
- AI diagnostics companies
- Genomic sequencing firms
- Healthcare data analytics platforms
- Biotech AI startups
Competitive advantages:
- Proprietary data scale
- Clinical integration
- Pharmaceutical partnerships
- Oncology specialization
Weaknesses:
- Capital intensity
- Reimbursement exposure
- Regulatory oversight
In healthcare, moats form slowly. But once formed, they’re hard to break.
Tempus AI Stock Technical Analysis
Let’s switch gears.
Fundamentals tell you what to buy. Technicals tell you when.
Investors track:
- 50-day moving average
- 200-day moving average
- Relative Strength Index (RSI)
- Volume trends
If the 50-day crosses above the 200-day, traders call that a golden cross.
If RSI dips below 30, the stock may be oversold.
Short-term traders use these signals. Long-term investors focus more on fundamentals.
Tempus AI Stock Forecast 2025
Forecasting isn’t magic. It’s scenario modeling.
Base Case 2025
- Continued revenue growth above 30%
- Margin improvement in data services
- Reduced cash burn
- Growing pharma partnerships
Bull Case
- AI platform expansion
- Major pharma deals
- Break-even timeline accelerates
- Market multiple expands
Bear Case
- Reimbursement pressure
- Growth slowdown
- Dilution from capital raises
- Margin compression
2025 Projection Table
| Scenario | Revenue | Profitability | Stock Price Outlook |
|---|---|---|---|
| Bear | Slower growth | Loss persists | Downside volatility |
| Base | Strong growth | Improving margins | Gradual appreciation |
| Bull | Accelerated scale | Path to profit | Significant upside |
Tempus AI Stock Price Prediction 2030
Long-term forecasts require bold assumptions.
By 2030, success would likely require:
- International expansion
- Broader disease coverage beyond oncology
- Scalable AI SaaS revenue
- Sustained gross margin improvement
If Tempus evolves into a dominant AI healthcare data platform, valuation could expand meaningfully.
If growth stalls, multiple compression could hurt returns.
High reward. High risk.
Analyst Ratings and Price Targets
Wall Street typically evaluates growth stocks based on:
- Revenue visibility
- Pipeline strength
- Management execution
- Sector tailwinds
Analyst ratings generally fall into:
- Buy
- Hold
- Sell
Price targets reflect projected earnings multiples or revenue multiples.
Remember this:
Analysts update models quarterly. The market updates prices every second.
Institutional Ownership and Investor Activity
Institutional participation often signals confidence.
Key holders may include:
- Large asset managers
- Growth-focused funds
- Healthcare-focused ETFs
High institutional ownership can:
- Reduce volatility
- Increase liquidity
- Signal long-term backing
However, heavy fund ownership can also amplify downside if funds exit quickly.
Risk Factors Every Investor Should Consider
No serious investor ignores risk.
Regulatory Risk
Healthcare compliance isn’t optional. FDA frameworks matter.
Reimbursement Risk
Insurance coverage affects diagnostic revenue.
Cash Burn
Persistent losses can lead to dilution.
AI Hype Cycle
AI enthusiasm can inflate valuations quickly.
Competition
Data isn’t exclusive forever.
Risk doesn’t eliminate opportunity. It defines it.
Long-Term Growth Catalysts
Tempus AI’s potential growth drivers include:
- Oncology expansion
- Rare disease data platforms
- International partnerships
- AI-driven clinical trials
- Precision medicine adoption
Healthcare is slowly becoming data-driven. That shift favors companies with structured datasets.
Tempus AI Stock Performance History
Since its IPO, Tempus AI stock has experienced volatility typical of newly public AI companies.
Short-term price swings often reflect:
- Broader AI sector momentum
- Earnings reports
- Macroeconomic interest rate changes
- Institutional trading patterns
Long-term performance will depend on execution.
Tempus AI vs Other AI Stocks
| Factor | Tempus AI | Generic AI Software |
|---|---|---|
| Industry | Healthcare | Enterprise |
| Regulation | High | Moderate |
| Data Barrier | Strong | Variable |
| Margin Profile | Mixed | Often high |
| Volatility | Elevated | Elevated |
Healthcare AI has higher compliance barriers but stronger defensibility.
Is Tempus AI Stock a Buy or Sell?
This depends on your risk profile.
Consider Buying If:
- You believe AI will reshape healthcare
- You accept volatility
- You invest long-term
- You understand growth-stage risks
Avoid If:
- You need stable dividends
- You prefer profitable companies
- You dislike volatility
This isn’t a utility stock. It’s a growth engine in development.
Frequently Asked Questions About Tempus AI Stock
What is Tempus AI stock ticker?
TEM.
Is Tempus AI listed on NASDAQ?
Yes.
Is Tempus AI profitable?
Not yet consistently profitable. Growth-focused stage.
What drives Tempus AI stock price?
Revenue growth, AI adoption, earnings reports, market sentiment.
Is Tempus AI a long-term investment?
It can be for high-risk growth investors.
Final Verdict on Tempus AI Stock
Tempus AI stands at a compelling crossroads.
It combines:
- AI innovation
- Clinical data scale
- Pharma partnerships
- Rapid revenue growth
However, it also carries:
- Operating losses
- Capital intensity
- Competitive pressure
In the right portfolio, Tempus AI stock can serve as a high-growth exposure to AI-driven healthcare transformation.
Just don’t confuse potential with certainty.
Invest with clarity. Not excitement.
Tempus AI stock (TEM) remains one of the most intriguing AI healthcare plays on NASDAQ today. Its future depends on execution, discipline, and the continued rise of data-driven medicine.
For investors who understand the risks, it’s a stock worth watching closely.
